Cargando…

Genetic Polymorphisms of Hemostatic Factors and Thrombotic Risk in Non BCR-ABL Myeloproliferative Neoplasms: A Pilot Study

The most important complications of Philadelphianegagive (non BCR-ABL) myeloproliferative neoplasms (MPNs) are vascular events. Our aim was to evaluate the effects of single nucleotide polymorphisms (SNPs), platelet glycoproteins (GPs) (Ia/IIa, Ibα, IIb/IIIa and VI), von Willebrand factor (vWF), coa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dambrauskienė, R, Gerbutavičius, R, Ugenskienė, R, Jankauskaitė, R, Savukaitytė, A, Šimoliūnienė, R, Rudžianskienė, M, Gerbutavičienė, R, Juozaitytė, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596820/ https://www.ncbi.nlm.nih.gov/pubmed/28924539 http://dx.doi.org/10.1515/bjmg-2017-0005

Ejemplares similares

Antiphospholipid antibodies and the risk of thrombosis in myeloproliferative neoplasms
por: Dambrauskienė, Rūta, et al.
Publicado: (2023)

Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience
por: Dambrauskiene, Ruta, et al.
Publicado: (2015)

Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma: A prospective randomised study
por: Rudzianskiene, Milda, et al.
Publicado: (2017)

Investigation of prognostic value of polymorphisms within estrogen metabolizing genes in Lithuanian breast cancer patients
por: Savukaitytė, Aistė, et al.
Publicado: (2015)

Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms
por: Barcelos, Michelle Maccarini, et al.
Publicado: (2011)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms
por: Yang, Naery, et al.
Publicado: (2018)

BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing
por: Mroczkowska-Bękarciak, Aleksandra, et al.
Publicado: (2023)

Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL–Negative Myeloproliferative Neoplasms
por: Belliere, Julie, et al.
Publicado: (2020)

The immune landscape in BCR‐ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy
por: Strickland, Marie, et al.
Publicado: (2021)

Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms
por: Morishita, Soji, et al.
Publicado: (2023)

Duffy and Kidd Genotyping Facilitates Pretransfusion Testing in Patients Undergoing Long-Term Transfusion Therapy
por: Remeikiene, Diana, et al.
Publicado: (2014)

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients
por: Cassinat, Bruno, et al.
Publicado: (2020)

AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
por: Beitzen-Heineke, Antonia, et al.
Publicado: (2021)

Retrospective analysis of the clinical features of 172 patients with BCR-ABL1-negative chronic myeloproliferative neoplasms
por: Lin, Xiaolan, et al.
Publicado: (2020)

Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR–ABL-Negative Myeloproliferative Neoplasm
por: Allegra, Alessandro, et al.
Publicado: (2020)

Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm
por: Abbou, Norman, et al.
Publicado: (2022)

Recent advances in the bcr-abl negative chronic myeloproliferative diseases
por: Bennett, Michael, et al.
Publicado: (2006)

Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms
por: Kim, Hye-Ran, et al.
Publicado: (2013)

Mutational Analysis of SH2B3 in Korean Patients With BCR-ABL1 Negative Myeloproliferative Neoplasm
por: Kim, Namhee, et al.
Publicado: (2016)

Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study
por: Baek, Seung-Woo, et al.
Publicado: (2018)

Mutation profile in BCR-ABL1-negative myeloproliferative neoplasms: A single-center experience from India
por: Maddali, Madhavi, et al.
Publicado: (2021)

Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
por: Porto-Soares, Moysés Antonio, et al.
Publicado: (2020)

PB2187: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS IN 832 PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Wille, Kai, et al.
Publicado: (2023)

Associations of MDM2 and MDM4 Polymorphisms with Early-Stage Breast Cancer
por: Bartnykaitė, Agnė, et al.
Publicado: (2021)

TIRAP Rs8177376, Rs611953, Rs3802814, and Rs8177374 Polymorphisms and Their Association with Cervical Cancer Phenotype and Prognosis
por: Bekampytė, Justina, et al.
Publicado: (2022)

Atypical myeloproliferative neoplasm with concurrent BCR-ABL1 fusion and CALR mutation: A case report and literature review
por: Liu, Chunshui, et al.
Publicado: (2020)

Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms
por: Kim, Jinyong, et al.
Publicado: (2021)

Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives
por: Barosi, Giovanni, et al.
Publicado: (2023)

P1053: NEUTROPHIL-TO-LYMPHOCYTE AND PLATELET-TO-LYMPHOCYTE RATIO AS NOVEL PROGNOSTIC BIOMARKES IN BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Cvetkovic, Mirjana, et al.
Publicado: (2023)

siRNA Knockdown of REDD1 Facilitates Aspirin-Mediated Dephosphorylation of mTORC1 Target 4E-BP1 in MDA-MB-468 Human Breast Cancer Cell Line
por: Savukaitytė, Aistė, et al.
Publicado: (2021)

DDIT4 Downregulation by siRNA Approach Increases the Activity of Proteins Regulating Fatty Acid Metabolism upon Aspirin Treatment in Human Breast Cancer Cells
por: Savukaitytė, Aistė, et al.
Publicado: (2023)

Defining the Thrombotic Risk in Patients with Myeloproliferative Neoplasms
por: Vianello, Fabrizio, et al.
Publicado: (2011)

Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms
por: Papageorgiou, Loula, et al.
Publicado: (2022)

The Role of Matrix Metalloproteinase Single-Nucleotide Polymorphisms in the Clinicopathological Properties of Breast Cancer
por: Bartnykaitė, Agnė, et al.
Publicado: (2022)

The Investigation of Associations between TP53 rs1042522, BBC3 rs2032809, CCND1 rs9344, EGFR rs2227983 Polymorphisms and Breast Cancer Phenotype and Prognosis
por: Bekampytė, Justina, et al.
Publicado: (2021)

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007)

Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α
por: Aruna,, et al.
Publicado: (2018)

JAK2, CALR, and MPL Mutation Profiles in BCR-ABL Negative Myeloproliferative Neoplasms, a Referral Center Experience in the Middle East
por: Safavi, Moeinadin, et al.
Publicado: (2021)

The Prevalence of TET2 Gene Mutations in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms (MPN): A Systematic Review and Meta-Analysis
por: Chia, Yuh Cai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_avfsk39aqephae7ieahjivo34j